By Philips ∙ Jun 12, 2017 ∙ 2 min read

iFR clinical data

Cardiology

Image-guided therapy

iFR patient study

Backed by a decade of data
Be confident in your treatment decisions with Philips iFR*
 
 

iFR is the global gold standard among resting indices, with 20,000 patients* studied and a Class IA recommendation in the ACC/AHA/SCAI, ESC and JSC Guidelines.1, 3-4 This is backed by clinical evidence and patient outcomes showing reduced costs, procedural time and patient discomfort.2 iFR also provides advanced guidance with iFR pullback and co-registration for PCI planning throughout the entire case. Learn more about the latest iFR patient studies and view the latest 5-year outcomes update.

Article at a glance

  • DEFINE PCI
  • Objective
  • Trial design
  • Results
  • DEFINE FLAIR and iFR Swedeheart
  • Consistent patient outcomes
  • Superior value

iFR Clinical evidence

DEFINE PCI

 

Unseen focal lesions cause residual ischemia. The DEFINE PCI study used iFR pullback to understand the rate and causes of residual ischemia in 500 patients undergoing contemporary PCI. Early results find that residual ischemia is common, and causes are treatable.2,5

Objective

  • Understand residual ischemia as mapped by iFR pullback after successful angiographic PCI and its implications for procedural improvement.

Trial design

  • Primary endpoint: rate of residual ischemia (iFR<0.90) after angiographically successful PCI (residual diameter stenosis < 50% in any treated lesion)
  • Multi-center, prospective study in 22 US and six international centers
  • N=500 patients with CAD and iFR < 0.90 in at least one coronary artery with tandem, diffuse or multi-vessel intermediate lesions
  • Blinded iFR pullback to assess inschemia after PCI
  • One year patient follow-up

Results6

  • One in four patients with angiographically successful PCI left the cath lab with residual ischemia.
  • 68% relative reduction in clinical events at one year follow-up among patients achieving post-PCI iFR ≥ 0.95 (p-value=0.04)
  • Of the patients with residual ischemia, 81.6% were caused by an untreated angiographically inapparent physiologically focal stenosis (≤ 15 mm).
  • The final picture is often incomplete. iFR co-registration uncovers focal ischemia producing lesions missed visually.

DEFINE FLAIR and iFR Swedeheart

DEFINE Flair and iFR Swedeheart are 2 prospective randomized controlled studies published in the prestigious New England Journal of Medicine and combined represent the largest physiology clinical dataset with more than 4500 patients.7,8 Learn more DEFINE FLAIR, iFR Swedeheart.

Proven Outcomes Graph 1

Consistent patient outcomes using iFR guided strategy, as with FFR

Image of Consistent patient outcomes using iFR guided strategy, as with FFR
Graph for Consistent patient outcomes using iFR guided strategy

* MACE rates at 5-years: 21.5% iFR vs. 19.9% FFR (HR 1.09; 95% CI: 0.90, 1.33)

Superior value

Reduced costs per patient

iFR Swedeheart found that on average, compared to FFR, iFR resulted in:

 

  • $896 dollars saved
     

Less procedural time

DEFINE FLAIR found that an iFR-guided strategy resulted in:

 

  • 10% reduction in procedural time
  • 40.5 minutes (iFR arm) vs. 45.0 minutes (FFR arm) [p<0.001]
     

Improved care

The two trials further established that an iFR-guided strategy enables a faster procedure while almost completely eliminating severe patient symptoms compared to an FFR-guided strategy.

 

  • DEFINE FLAIR reported a 90% reduction in patient discomfort.
  • iFR Swedeheart reported that with no hyperemic agent, you can achieve a 95.7% reduction in patient discomfort using an iFR-guided strategy.

We are always interested in engaging with you.

Let us know how we can help.

1
Select your area of interest
2
Contact details

   

*Philips data on file D063129-00
 

Footnotes

 

1. Lawton J. et al. 2021 ACC/AHA/SCAI Guideline for Coronary Artery Revascularization. JACC. 2022;79(2):e21-e129. 

2. Gotberg M, et al. Instantaneous wave-free ratio compared with fractional flow reserve in PCI: A cost-minimization analysis. Int J Cardiol 2021 1;344:54-59. 

3. ESC/EACTS Guidelines on myocardial revascularization: The task force on myocardial revascularization of the European Society of Cardiology (ESC) and European Association for Cardio-thoracic Surgery (EACTS). Eur Heart J. 20218;00:1-96.

4.Nakamura M, et al. JCS/JSCVS 2018 Guideline on Revascularization of Stable Coronary Artery Disease. Circ J 2019; 83:1085–1196.                                              

5.Jeremias A et al. Blinded physiological assessment of residual ischemia after successful angiographic percutaneous coronary Intervention: The DEFINE PCI Study. JACC Cardiovasc Interv. 2019 Oct 28;12(20):1991-2001.

6.Patel M., et al. 1-Year outcomes of blinded physiological assessment of residual ischemia after successful PCI. JACC Cardiol Interv. 2022;15(1):52-61.

7.Davies JE, et al., Use of the Instantaneous Wave-free Ratio or Fractional Flow Reserve in PCI. N Engl J Med. 2017 24-1834.                                                    

8.Gotberg M, et al. iFR-SWEDEHEART Investigators. Instantaneous Wave-free Ratio versus Fractional Flow Reserve to Guide PCI. N Engl J Med. 2017 May 11;376(19):1813-1823.

You are about to visit a Philips global content page

Continue

You are about to visit a Philips global content page

Continue

Our site can best be viewed with the latest version of Microsoft Edge, Google Chrome or Firefox.